Nixon Peabody
Bank of America
You are here:  Home  >  Latest news  >  Current Article

Amgen shares jump on good news from melanoma drug study

By   /   Wednesday, March 20th, 2013  /   Comments Off on Amgen shares jump on good news from melanoma drug study

    Print       Email
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”20-09-2012″ enddate=”20-03-2013″ width=”300″ height=”245″]

Shares of Thousand Oaks-based Amgen rose in light trading on March 20 after the company announced favorable results from a drug that treats advanced melanoma.
The drug, dubbed T-VEC, uses a virus to infiltrate tumors and shrink them. It achieved positive results in a large number of patients receiving standard drug therapies.  According to the study Amgen cited, some 16 percent of patients achieved positive results versus just 2 percent using conventional therapies.
The Associated Press said the results for T-VEC  show that  similar vaccines other companies are developing could also be effective in treating advanced melanoma. Amgen, quoting earlier research, said that although melanoma accounts for a small fraction of all skin cancers, it does account for 75 percent of all skin cancer deaths.
Shares of Amgen rose $1.50 or slightly less than 2 percent to $94 at the close of business on March 20.  T-VEC, which is injected directly into the tumors just below the skin at two-week intervals, causes direct destruction of tumors while also “stimulating a systemic anti-tumor response,” Amgen said.
About 400 patients took part in the study, which involved 18 months of treatments. The treatments continue for patients getting positive results, Amgen said.

    Print       Email

You might also like...

Delta Airlines halts service to Santa Barbara airport

Read More →